Trial
NCT03719898
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
—
Condition
Anaplastic Large Cell Lymphoma, ALK-Positive
Intervention
Brigatinib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-05